There were 1,155 press releases posted in the last 24 hours and 430,264 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Retrotope Receives FDA Clearance to Commence RT001 Phase 2/3 Clinical Trial in Patients with Infantile Neuroaxonal Dystrophy (INAD)

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image